| Literature DB >> 30068283 |
Amirhosein Maali1, Amir Atashi2, Sasan Ghaffari3, Reza Kouchaki4, Fereshteh Abdolmaleki4, Mehdi Azad4.
Abstract
Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Leukemia; gene therapy; iHSC; iPSC; malignancy modeling; miRNAs; reprogrammed NK cells; treatment.
Mesh:
Year: 2018 PMID: 30068283 DOI: 10.2174/1574888X13666180731155038
Source DB: PubMed Journal: Curr Stem Cell Res Ther ISSN: 1574-888X Impact factor: 3.828